Sponsors (2)
The bill strengthens national‑security protections for U.S. biotechnology and medical supply chains by expanding screening and prohibiting certain outbound deals, at the cost of reduced foreign capital and collaborations, higher compliance burdens for startups, and some risk of slower patient access and administrative strain.
Taxpayers, federal agencies, U.S. biotech firms, researchers, and patients gain stronger national-security controls that can block outbound investments and licenses that would transfer critical biotechnology IP or manufacturing know‑how to PRC‑controlled entities.
Patients, hospitals, and domestic manufacturers gain clearer protection for medical supply chains because the bill explicitly covers pharmaceuticals, biologics, and therapeutics for review, reducing the risk of foreign control over critical medical development and production.
Financial institutions, firms, and regulators get clearer, more consistent rules (aligned with existing semiconductor/AI controls) and a more predictable CFIUS/Treasury review scope for biotech deals, lowering regulatory uncertainty about which transactions are covered.
Small biotech firms, researchers, investors, and financial firms may lose access to foreign capital and partnerships, reducing funding and collaboration that can accelerate drug development and commercialization.
Startups and smaller companies will face higher compliance costs, more transaction delays, and increased legal and administrative burdens from expanded screening, notification, and mitigation requirements.
Patients (especially those with chronic conditions) could experience higher prices or slower access to therapeutics if companies pass compliance costs along or if supply‑chain and research collaborations are constrained.
Based on analysis of 5 sections of legislative text.
Adds biotech (pharma, biologics, clinical R&D, and related IP) to DPA outbound transaction screening, requires Treasury to define biotechnology by rule, and mandates a DoD report on China investment risks.
Official title: Amend title VIII of the Defense Production Act of 1950 to include biotechnology in the definitions of "prohibited technology" and "notifiable technology", and for other purposes.
Introduced August 6, 2026 by John Peter Ricketts · Last progress August 6, 2026
Adds biotechnology (pharmaceuticals, biologics, clinical R&D, and related IP/know‑how) to the Defense Production Act’s national security transaction rules, making licensing and certain outbound investments subject to prohibition or notification. Requires the Treasury to issue a regulatory definition of “biotechnology” within one year, and directs the Department of Defense to report within 60 days on national security risks from U.S. capital flowing into China’s biotech sector. The policy aims to treat strategic biotech transfers like semiconductors and AI by prioritizing licensing, joint ventures, and equity investments for scrutiny, excluding agricultural biotech and basic academic research, and creating a process to identify covered transactions and foreign actors of concern.